1. ALLA AKTIER
  2. NYHETER
  3. PROLIGHT DIAGNOSTICS

Prolight Diagnostics

Nyheter Prolight Diagnostics Nyheter alla bolag
eToro Trading Platform Advertisement
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

Prolight Diagnostics publishes investor letter for December 2024

In 2024, Prolight has achieved many business-critical milestones, positioning the company optimally for 2025 and on track for its planned commercial launch in 2026.

link to the investor letter: https://prolightdx.com/PRLD-Investerarbrev-dec-2024-EN.pdf

For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com

About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
 
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments
Prolight Diagnostics publishes investor letter for December 2024

Datum 2024-12-17, kl 11:00
Källa MFN
Bifogade filer
Prolight Diagnostics publishes investor letter for December 2024